REACTIVITY OF MONOCLONAL-ANTIBODY DF3 WITH A HIGH-MOLECULAR-WEIGHT ANTIGEN EXPRESSED IN HUMAN OVARIAN CARCINOMAS
- 1 October 1986
- journal article
- research article
- Vol. 46 (10) , 5189-5194
Abstract
We have previously described the monoclonal antibody (MAb) DF3, prepared against a human breast carcinoma. MAb DF3 reacts with a high molecular weight glycoprotein detectable in human breast carcinomas and in human milk. Previous studies have demonstrated that DF3 antigen levels are elevated in the plasma of patients with breast and ovarian cancer. The present study has further examined the reactivity of MAb DF3 with human ovarian carcinomas. Immunoperoxidase staining demonstrated reactivity of MAb DF3 with 95% of benign, borderline, and malignant tumors (serous, mucinous, and endometrioid) of the ovary. Furthermore, malignant tumors contained cytoplasmic DF3 antigen while benign tumors expressed the antigen only on apical surfaces. Western blot analyses demonstrated that the MAb DF3 reactive ovarian antigen (DF3-O) was a glycoprotein with a heterogenous molecular weight ranging between 300,000 and 450,000. This antigen was detectable by immunofluorescence on the cell surface of five of six cultured human ovarian carcinoma cell lines. The extent of cell surface reactivity with MAb DF3 was equivalent to or greater than the obtained with MAb OC125, an antibody generated against coelomic epithelium and developmental amnion. Furthermore, uptake of 125I-labeled MAb DF3 by human ovarian carcinoma xenografts in athymic mice was 5.4- and 6.2-fold higher than the respective uptake noted in liver and control tumor (P = 0.031). These findings suggest that DF3-O antigen is similar if not identical to the antigen detected in human breast carcinomas by MAb DF3. Thus, MAb DF3 may be a useful reagent in immunodiagnostic evaluation of patients with ovarian cancer.This publication has 25 references indexed in Scilit:
- Immunopathologic Characterization of a Monoclonal Antibody that Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell TypesAmerican Journal of Clinical Pathology, 1983
- TARGETING OF IODINE-123-LABELLED TUMOUR-ASSOCIATED MONOCLONAL ANTIBODIES TO OVARIAN, BREAST, AND GASTROINTESTINAL TUMOURSThe Lancet, 1982
- A NEW MARKER FOR HUMAN CANCER CELLS. 2. IMMUNOHISTOCHEMICAL DETECTION OF THE Ca ANTIGEN IN HUMAN TISSUES WITH THE Ca1 ANTIBODYThe Lancet, 1982
- A NEW MARKER FOR HUMAN CANCER CELLS. 1. THE Ca ANTIGEN AND THE Cal ANTIBODYThe Lancet, 1982
- A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populationsInternational Journal of Cancer, 1982
- MONOCLONAL-ANTIBODIES RECOGNIZING TUMOR-ASSOCIATED ANTIGEN OF HUMAN OVARIAN MUCINOUS CYSTADENOCARCINOMAS1982
- Reactivity of a monoclonal antibody with human ovarian carcinoma.Journal of Clinical Investigation, 1981
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- ESTABLISHMENT AND CHARACTERIZATION OF 3 NEW CONTINUOUS CELL LINES DERIVED FROM HUMAN BREAST CARCINOMAS1978